Financial Strategy And Market PotentialPursuing LCA5 and BEST1 will require significantly smaller studies with low capital needs, providing financial rationale for Opus' strategic pivot.
Gene Therapy AdvancementsThe acquisition adds seven AAV-based gene therapies for inherited retinal disease (IRD) to the pipeline, enhancing the company's capabilities in innovative treatments.
Partnership And Revenue OpportunitiesOcuphire will manage the trials with partner Viatris, who will reimburse Ocuphire for agreed-to budgeted costs related to Ryzumvi development through FDA approval, paving the way for meaningful royalties.